gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 4494 131410-48-5

Description:

MoleculeDescription

Synonyms:

  • omniscan
  • gadodiamide
for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions
  • Molecular weight: 573.66
  • Formula: C16H26GdN5O8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.79 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.46 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 8, 1993 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2250.51 48.76 349 2661 4207 63481805
Skin hypertrophy 411.79 48.76 79 2931 3312 63482700
Skin induration 409.52 48.76 78 2932 3145 63482867
Skin tightness 310.37 48.76 65 2945 4251 63481761
Skin fibrosis 214.41 48.76 37 2973 843 63485169
Fibrosis 199.54 48.76 45 2965 4147 63481865
Skin hyperpigmentation 153.96 48.76 39 2971 5882 63480130
Joint contracture 129.81 48.76 27 2983 1697 63484315
Joint range of motion decreased 129.54 48.76 51 2959 32377 63453635
Scar 105.18 48.76 35 2975 13747 63472265
Emotional distress 95.27 48.76 41 2969 32508 63453504
Skin discolouration 92.51 48.76 42 2968 37786 63448226
Anhedonia 80.27 48.76 27 2983 10947 63475065
Peau d'orange 77.20 48.76 12 2998 138 63485874
Oedema peripheral 73.14 48.76 65 2945 189446 63296566
Erythema 71.25 48.76 62 2948 175689 63310323
Joint stiffness 70.50 48.76 36 2974 41833 63444179
Mobility decreased 64.26 48.76 50 2960 121109 63364903
Skin plaque 62.94 48.76 21 2989 8299 63477713
Extremity contracture 62.21 48.76 14 2996 1271 63484741
Muscle contracture 60.91 48.76 14 2996 1397 63484615
Pain 60.07 48.76 117 2893 740511 62745501
Deformity 59.63 48.76 22 2988 11662 63474350
Magnetic resonance imaging head abnormal 55.97 48.76 14 2996 1999 63484013
Contrast media deposition 54.79 48.76 8 3002 58 63485954

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2332.22 47.16 387 2811 3618 34950115
Skin hypertrophy 385.81 47.16 80 3118 2549 34951184
Skin induration 365.86 47.16 74 3124 2077 34951656
Skin tightness 362.44 47.16 74 3124 2179 34951554
Joint contracture 243.41 47.16 52 3146 1909 34951824
Joint range of motion decreased 243.02 47.16 67 3131 7245 34946488
Skin fibrosis 225.90 47.16 44 3154 1008 34952725
Fibrosis 182.07 47.16 43 3155 2493 34951240
Scar 167.96 47.16 48 3150 5896 34947837
Extremity contracture 132.91 47.16 27 3171 769 34952964
Deformity 130.50 47.16 30 3168 1542 34952191
Emotional distress 127.84 47.16 49 3149 14977 34938756
Mobility decreased 121.94 47.16 58 3140 30070 34923663
Joint stiffness 112.72 47.16 41 3157 10832 34942901
Anhedonia 107.05 47.16 36 3162 7549 34946184
Pain 87.31 47.16 100 3098 204575 34749158
Oedema peripheral 86.74 47.16 78 3120 119734 34833999
Injury 84.16 47.16 40 3158 20647 34933086
Skin discolouration 71.03 47.16 34 3164 17811 34935922
Skin disorder 70.16 47.16 31 3167 13524 34940209
Musculoskeletal stiffness 65.50 47.16 45 3153 46635 34907098
Skin hyperpigmentation 64.45 47.16 20 3178 3244 34950489
Anxiety 55.22 47.16 56 3142 99372 34854361
Gait inability 49.35 47.16 28 3170 20730 34933003
Peau d'orange 49.28 47.16 9 3189 143 34953590
Muscle contracture 48.74 47.16 13 3185 1231 34952502

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 3162.99 54.84 504 4269 5656 79733959
Skin hypertrophy 627.02 54.84 124 4649 4804 79734811
Skin induration 600.81 54.84 118 4655 4407 79735208
Skin tightness 536.27 54.84 111 4662 5411 79734204
Skin fibrosis 342.84 54.84 62 4711 1462 79738153
Joint contracture 293.60 54.84 59 4714 2465 79737150
Joint range of motion decreased 267.31 54.84 93 4680 33189 79706426
Fibrosis 244.67 54.84 58 4715 5251 79734364
Scar 196.84 54.84 61 4712 15135 79724480
Biopsy brain abnormal 176.47 54.84 21 4752 8 79739607
Skin hyperpigmentation 173.52 54.84 47 4726 7256 79732359
Oedema peripheral 140.83 54.84 118 4655 252170 79487445
Joint stiffness 138.06 54.84 61 4712 40769 79698846
Skin discolouration 134.55 54.84 60 4713 40974 79698641
Emotional distress 132.84 54.84 59 4714 39910 79699705
Anhedonia 124.74 54.84 43 4730 14855 79724760
Mobility decreased 119.26 54.84 80 4693 122095 79617520
Extremity contracture 117.82 54.84 26 4747 1706 79737909
Deformity 113.64 54.84 36 4737 9569 79730046
Peau d'orange 103.92 54.84 18 4755 327 79739288
Skin disorder 99.75 54.84 46 4727 33897 79705718
Pain 93.08 54.84 157 4616 703645 79035970
Erythema 88.03 54.84 86 4687 223204 79516411
Muscle contracture 84.61 54.84 21 4752 2296 79737319
Skin plaque 82.18 54.84 29 4744 10716 79728899
Injury 69.00 54.84 48 4725 77448 79662167
Musculoskeletal stiffness 68.14 54.84 67 4706 174941 79564674
Magnetic resonance imaging head abnormal 66.86 54.84 18 4755 2708 79736907
Skin exfoliation 63.26 54.84 40 4733 55060 79684555
Pruritus 62.79 54.84 96 4677 394552 79345063
Muscle tightness 62.75 54.84 25 4748 12889 79726726
Anxiety 59.97 54.84 74 4699 248438 79491177
Magnetic resonance imaging abnormal 58.17 54.84 17 4756 3442 79736173
Gait disturbance 56.97 54.84 66 4707 207440 79532175
Muscular weakness 56.07 54.84 58 4715 160671 79578944

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08CA03 VARIOUS
CONTRAST MEDIA
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Paramagnetic contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA MoA N0000175862 Magnetic Resonance Contrast Activity
FDA EPC N0000180184 Paramagnetic Contrast Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Magnetic resonance imaging indication 113091000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04284 KEGG_DRUG
4020689 VUID
N0000148302 NUI
4020689 VANDF
CHEBI:31642 CHEBI
CHEMBL1200346 ChEMBL_ID
C064925 MESH_SUPPLEMENTAL_RECORD_UI
6636 INN_ID
DB00225 DRUGBANK_ID
84F6U3J2R6 UNII
41144 RXNORM
10205 MMSL
4771 MMSL
d04083 MMSL
004259 NDDF
354088005 SNOMEDCT_US
396067007 SNOMEDCT_US
C0082646 UMLSCUI
153921 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0691 INJECTION 287 mg INTRAVENOUS NDA 28 sections
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0691 INJECTION 287 mg INTRAVENOUS NDA 28 sections